Literature DB >> 14728801

LRH-1/hB1F and HNF1 synergistically up-regulate hepatitis B virus gene transcription and DNA replication.

Yan Ning Cai1, Qing Zhou, Yu Ying Kong, Mei Li, Benoit Viollet, You Hua Xie, Yuan Wang.   

Abstract

Enhancer II (ENII) is one of the critical cis-elements in the Hepatitis B Virus (HBV) genome for the hepatic viral gene transcription and DNA replication. The liver-specific activity of ENII is regulated by multiple liver-enriched transcription factors, including LRH-1/hB1F, HNF1, HNF3b, HNF4 and C/EBP. Knowledge on the interplay of these important factors is still limited. In this study, we demonstrate a functional synergism between the orphan nuclear receptor LRH-1/hB1F and the homeoprotein HNF1 in up-regulating the liver-specific activity of ENII. This synergism is sufficient for initiating the viral gene transcription and DNA replication in non-hepatic cells. We have defined the activation domains in hB1F and HNF1 that contribute to the synergism. We further show that hB1F and HNF1 can interact directly in vitro and have mapped the domains required for this interaction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14728801     DOI: 10.1038/sj.cr.7290187

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  18 in total

Review 1.  Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B.

Authors:  Bidisha Mitra; Roshan J Thapa; Haitao Guo; Timothy M Block
Journal:  Antiviral Res       Date:  2018-08-24       Impact factor: 5.970

2.  A Structural Investigation into Oct4 Regulation by Orphan Nuclear Receptors, Germ Cell Nuclear Factor (GCNF), and Liver Receptor Homolog-1 (LRH-1).

Authors:  Emily R Weikum; Micheal L Tuntland; Michael N Murphy; Eric A Ortlund
Journal:  J Mol Biol       Date:  2016-10-27       Impact factor: 5.469

3.  Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription.

Authors:  Shirine Benhenda; Aurélie Ducroux; Lise Rivière; Bijan Sobhian; Michael D Ward; Sarah Dion; Olivier Hantz; Ulrike Protzer; Marie-Louise Michel; Monsef Benkirane; Oliver J Semmes; Marie-Annick Buendia; Christine Neuveut
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

Review 4.  Core promoter: a critical region where the hepatitis B virus makes decisions.

Authors:  Jorge Quarleri
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

5.  Transactivation of the hepatitis B virus core promoter by the nuclear receptor FXRalpha.

Authors:  Christophe Ramière; Caroline Scholtès; Olivier Diaz; Vinca Icard; Laure Perrin-Cocon; Mary-Anne Trabaud; Vincent Lotteau; Patrice André
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

Review 6.  Roles of hepatocyte nuclear factors in hepatitis B virus infection.

Authors:  Doo Hyun Kim; Hong Seok Kang; Kyun-Hwan Kim
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

Review 7.  Virological Basis for the Cure of Chronic Hepatitis B.

Authors:  Jin Hu; Junjun Cheng; Liudi Tang; Zhanying Hu; Yue Luo; Yuhuan Li; Tianlun Zhou; Jinhong Chang; Ju-Tao Guo
Journal:  ACS Infect Dis       Date:  2018-06-25       Impact factor: 5.084

Review 8.  Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach.

Authors:  Francisco Rodriguez-Frias; Maria Buti; David Tabernero; Maria Homs
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

9.  ZEB2 inhibits HBV transcription and replication by targeting its core promoter.

Authors:  Qiao He; Wanyu Li; Jihua Ren; Yecai Huang; Ying Huang; Qin Hu; Juan Chen; Weixian Chen
Journal:  Oncotarget       Date:  2016-03-29

10.  The Tudor domain protein Spindlin1 is involved in intrinsic antiviral defense against incoming hepatitis B Virus and herpes simplex virus type 1.

Authors:  Aurélie Ducroux; Shirine Benhenda; Lise Rivière; O John Semmes; Monsef Benkirane; Christine Neuveut
Journal:  PLoS Pathog       Date:  2014-09-11       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.